about
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Generation and analysis of the improved human HAL9/10 antibody phage display libraries.Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.Interleukin-23: a key cytokine in inflammatory diseases.Briakinumab for the treatment of plaque psoriasis.Cytokine-based therapy in psoriasis.Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?Targeting the adaptive immune system: new strategies in the treatment of atherosclerosis.Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates.Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis.Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response.Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.Developmental and reproductive toxicology studies in IL-12p40 knockout mice.Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?
P2860
Q34112840-8853CBF1-7915-4EB8-9041-05C1141F500EQ35608279-1F23FCD5-9BC5-4494-8755-725D17FE482AQ35616449-85021A32-8C55-4A07-8130-CF2ED53405C2Q37773243-B5429056-F81B-4A30-B17B-F9225DE2A360Q37777431-850737B9-9D79-4966-8FDC-969C3868908EQ37876404-38FB5AA3-174A-408C-8EC7-CCD19348A3F0Q37955218-A0567739-43B5-403A-B2D2-B33C231840DEQ37994612-5E152339-283A-4827-BD48-BA0AFF89ACA9Q38023581-857C6AF8-30BE-4E1A-8BDE-977FED0FAFD2Q38406177-8CF45746-9BFF-40E2-B73D-20212C270E31Q39277950-F4971264-3DB2-444C-AA93-B5F9F5BDCC9DQ41146021-8FE2D990-3903-4339-9CEB-CA4A96E7D64DQ42690764-CDE198CB-F0E9-4AF0-BACC-935F84472AA6Q48132175-DEA52949-1A29-4DBB-9DEE-A232CD713495Q51497509-B46D8B05-B16F-4A69-A61B-3A515D2D8B4FQ52887542-14E41810-7D02-4D8C-AAF4-BBA7F418DCE2
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Briakinumab.
@ast
Briakinumab.
@en
Briakinumab.
@nl
type
label
Briakinumab.
@ast
Briakinumab.
@en
Briakinumab.
@nl
prefLabel
Briakinumab.
@ast
Briakinumab.
@en
Briakinumab.
@nl
P2860
P50
P1476
Briakinumab.
@en
P2093
Xinaida Taligare Lima
P2860
P304
P356
10.1517/14712590903092188
P407
P577
2009-08-01T00:00:00Z